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Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with 
dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular 
endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active 
treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis 
aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology.
Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled 
in the study between September 2007 and September 2015. All of the patients received chemotherapy with 
cisplatin (30 mg/sqm, days 1–3q21) and oral etoposide (50 mg, days 1–15q21) (mPE) and 14 of them also 
received bevacizumab 5 mg/kg on the day 3q21 (mPEBev regimen). 
Results: This treatment showed a disease control rate of 71% with a mean progression free survival (PFS) 
and overall survival (OS) of 13.6 and 17 months respectively. After 4 treatment courses, 6 patients showing 
a remarkable tumor shrinkage, underwent to radical surgery, attaining a significant advantage in term of 
survival (P=0.048). Kaplan-Meier and log-rank test identified the longest survival in patients presenting 
low baseline levels in neutrophil-to-lymphocyte ratio (NLR) (P=0.05), interleukin (IL) 17A (P=0.036), 
regulatory-T-cells (Tregs) (P=0.020), and activated CD83+ dendritic cells (DCs) (P=0.03). 
Conclusions: These results suggest that the mPE +/− bevacizumab regimen is feasible and should be 
tested in comparative trials in advanced squamous-NSCLC (sqNSCLC). Moreover, its immune-biological 
effects strongly suggest the investigation in sequential combinations with immune check-point inhibitors. 
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Introduction 
Non-small cell lung cancer (NSCLC) is the most common 
malignancy and the leading cause of cancer death 
representing about 17% of new cancer diagnoses worldwide 
(1,2). Squamous-NSCLC (sqNSCLC) (3) represents the 
second most common histology (30% of all cases), and for 
these patients the only chance of cure is represented by 
radical surgery that is possible only in case of loco-regional 
disease (stage I–IIIA) and good performance status. The 
standard treatment for advanced sqNSCLC patients (stage 
IIIB–IV) with a good performance status is represented 
by chemotherapy with platinum derivatives cisplatin or 
carboplatin in combination with gemcitabine, paclitaxel or 
nab-paclitaxel and, eventually, radiotherapy for palliation 
(4-6). In this light, patients with advanced sqNSCLC have a 
poor prognosis with a survival that usually does not exceed 
9–10 months and with no real improvement attained with 
systemic treatments in the last three decades (4). The long-
lasting therapeutic failure for advanced sqNSCLC patients 
has been recently interrupted by the positive results of 
clinical trials testing programmed-cell-death-receptor-1 
(PD-1)/programmed-cell-death-receptor l igand-1 
(PDL-1) immune-checkpoint blockade with monoclonal 
antibodies (mAbs) such as Nivolumab, Pembrolizumab or 
Atezolizumab. These results lead the European Medicines 
Agency (EMA) and the Food and Drug Administration 
(FDA) to approve some of these agents for the second line 
treatment of advanced sqNSCLC patients (7-10). We have 
previously designed a multistep phase I/II clinical trial 
(Beva 2007 study) aimed to investigate the toxicity, the 
biological and anti-tumor activity of a novel metronomic 
chemotherapy regimen with dose-fractioned cisplatin 
and oral etoposide (mPE) +/− bevacizumab (mPEBev) in 
NSCLC patients, including the squamous cell histology. 
Metronomic chemotherapy is an emerging treatment 
modality for cancer patients based on the use of cytotoxic 
drugs administered at lower dosage for a prolonged period 
of time (11). This modality allows to achieve a higher 
dose intensity of cytotoxic drugs compared to traditional 
modality avoiding dangerous spikes in blood concentration 
(12,13). Some of these properties may be enforced by a 
rationale combination with bevacizumab, a humanized 
IgG1 to the vascular endothelial growth factor (VEGF), 
able to increase the efficacy of standard poly-chemotherapy 
in NSCLC patients (14,15). Metronomic chemotherapy 
and VEGF deprivation by bevacizumab synergize as both 
anti-angiogenic and immune-modulating activity, resulting 
in a significant antitumor activity. Even though considered 
a very active drug for NSCLC patients, bevacizumab 
was not approved for the treatment of sqNSCLC due 
to the high risk of bleeding reported in the early trials. 
This risk was correlated to the central localization of the 
disease that often infiltrates the large mediastinum vessels. 
Considering the lowest dosage and chronic administration 
of the treatment, our trial also included NSCLC patients 
with squamous histology with low risk of bleeding. The 
mPEBev regimen resulted safe and very active with a 
partial response and disease stabilization rate of 68.8% and 
17.8%, respectively, and a progression free survival (PFS) of 
9.5 months (16,17). The treatment was associated to a fast 
and progressive decline in the tumor blood flux (perfusional 
CT scan) paralleled by a progressive decline in the serum 
levels of pro-angiogenic and immune-modulating cytokines 
(VEGF, angiopoietin-1, thrombospondin-1, follistatin, 
IFNɣ, IL-4 and IL-17A), and inflammatory markers 
[neutrophil-lymphocyte ratio (NLR), C reactive protein 
(CRP), lactate dehydrogenase (LDH), myeloperoxidase] 
(17,18). Additional in vivo and ex vivo immunological studies 
also revealed a treatment-related improvement in both 
tumor antigen processing and presentation ability by active 
peripheral dendritic cells (DCs) and a more efficient tumor-
specific cytotoxic T cell (CTL) response (18) suggesting 
that either mPE or mPEBev regimens may improve the 
micro-environmental conditions necessary for an efficient 
anti-tumor activity by antigen specific T cell effectors. At 
this purpose, we performed a retrospective analysis aimed 
to evaluate the antitumor activity of the mPE regimen 
+/− bevacizumab, in the subset of patients with sqNSCLC 
histology enrolled in the second step of the BEVA2007 trial 
and, also, carried out a statistical analysis aimed to identify 
possible immunobiological markers predictive of positive 
outcome in these patients.
Methods 
Study design
The study protocol code #BEVA2007 (2008-006051-40) 
was a two-step phase I/II clinical trial, performed in 
accordance to the good clinical practice guidelines and was 
approved by the Bioethics Committee of the University 
of Siena as described in previous reports (16-18). The 
first step of the study included 25 patients, who were 
sub-divided in five cohorts receiving escalating dosage 
of bevacizumab. Cohort 1 received mPE chemotherapy 
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alone, while cohort 2, 3, 4 and 5 received bevacizumab 
every three weeks, at the dosage of 2.5, 5, 7.5 and 10 mg/kg 
every three weeks. This first step revealed coincidence of 
bevacizumab maximal tolerated dose (MTD) and most 
effective biological dose (MEBD) at 5 mg/kg (16), which 
was chosen as standard dosage for the second step of the 
study. The inclusion criteria were: histological diagnosis 
of mNSCLC, performance status (ECOG) from 0 to 2, 
normal renal and hepatic function, WBC count more than 
2,500/mm3, hemoglobin more than 9 g/dL, platelet cell 
count more than 90,000/mm3, normal cardiac function. 
The exclusion criteria were: Central tumors with high risk 
of bleeding (excavated with large necrosis and infiltration of 
large arterial and venous structures) for bevacizumab use, a 
history of other severe cardiovascular disease, arrhythmia, 
second malignant tumors, signs of active infections. The 
trial included a calibration group of thirty patients who 
were aimed to receive the same metronomic chemotherapy 
and no bevacizumab. Four patients in the mPEBev group 
and two patients in the calibration group retired the consent 
and did not receive the treatment.
Treatment schedule
Eighty six patients received, every three weeks, iv. cisplatin 
(30 mg/sqm) on days 1–3 and daily oral etoposide (50 mg) 
on days 1–15 and bevacizumab, 5 mg/kg, on the day 3 
for a maximum of four consecutive courses (16-18). In 
the calibration group, twenty eight patients received the 
same metronomic chemotherapy with no bevacizumab 
administration. The response was assessed according to 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1.
Biological analysis and blood sampling
Peripheral blood samples (10 mL) were withdrawn at 
baseline and one hour before any treatment cycle for 
both serum and PBMC isolation. Serum derived from 
standard peripheral blood centrifugation and peripheral 
blood mononuclear cells (PBMCs), obtained by Ficoll-
Hypaque (Celbio S.P.A., Italy) gradient separation medium 
from heparinized blood samples, were immediately 
frozen and stored as described in previous studies (16-18). 
Lymphocytes, platelets, neutrophils and monocytes were 
evaluated by hemocytometric cell counts, while their feature 
was evaluated by microscope analysis. Flow cytometry was 
performed on patients’ PBMCs by carrying out standard 
multicolor immuno-cytoflurimetric analysis with conjugated 
anti-CD3, CD4, CD8, CD27, CD62L, CD19, CD16, 
CD56, CD25, FoxP3, CCR7, CD45Ra, CD11b, CD11c, 
CD14, CD15, all purchased by Bioscience, USA.
BioPlex assay
Blood samples were collected from a peripheral vein at 
baseline and after 3 treatment courses and kept on ice. 
Serum was collected by centrifugation (3,000 rpm for 
10 min at 4 ℃), aliquoted and stored at −80 ℃ until 
analyzed. A multiplex biometric ELISA-based immunoassay, 
containing dyed microspheres  conjugated with a 
monoclonal antibody specific for a target protein was used 
according to the manufacturer’s instructions (Bio-Plex, Bio-
Rad Lab., Inc., Hercules, CA, USA). Soluble molecules 
were measured using either commercially available kits 
or customized kits for the evaluation of the following 
cytokines: interleukin (IL)-4, IL-8, IL-10, IL-12, IL-17, 
interferon (IFN)ɣ, tumor necrosis factor (TNF)α, VEGF, 
Granulocyte-Colony Stimulating Factor (GCSF) and 
angiopoietin-2, as described in previous papers (16). Serum 
levels of all proteins were determined using a Bio-Plex 
array reader (Luminex, Austin, TX, USA) that quantifies 
multiplex immunoassays in a 96-well plate with very small 
fluid volumes. The analyte concentration was calculated 
using a standard curve, with software provided by the 
manufacturer (Bio-Plex Manager Software).
Statistical analysis
The between-mean differences were statistically analyzed 
using Stat View statistical software (Abacus Concepts, 
Berkeley, CA, USA). The results were expressed as the mean 
+/− standard deviation (SD) of four determinations made in 
three different experiments, and the differences determined 
using the 2-tail Student’s t-test for paired samples. In order 
to perform a survival analysis we divided the patients into 
two subgroups with low (L) and high (H) score, according 
to their respective median value of each specific marker or 
treatment related level change expressed as fold change to 
baseline value. Kaplan Meier’s method and Log-Rank test 
were used to evaluate PFS and OS and correlate them with 
patients’ associated variables. All analyses were performed 
by using SPSS statistical package, version 17.0. A P value of 
0.05 or less was considered statistically significant.
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Results
The BEVA2007 study was a multistep phase I–II trial 
aimed to investigate, in advanced NSCLC patients, the 
safety, immunobiological and antitumor activity of the 
mPE doublet +/− bevacizumab, an original metronomic 
chemo-biological regimen that showed significant anti-
angiogenic and immunological activity in previous studies 
(13,16-18). One hundred twenty advanced NSCLC patients 
were enrolled in the study between September 2007 
and September 2015 and one-hundred sixteen of them 
received the treatment. Of the 116 patients receiving the 
treatment, 62 patients presented a histological diagnosis of 
adenocarcinoma, 31 of squamous cell carcinoma and the 
remaining 23 of other NSCLC subtypes. We carried out 
our retrospective study in the squamous cell subset; in this 
group, there were 29 males and 2 females, with median age 
of 67 years and median performance status of 1, according 
to the ECOG score. At the time of diagnosis, 6 out of 31 
of these patients resulted in a stage IIIB and 25 out of 31 in 
a stage IV. Seventeen out of 31 patients received frontline 
chemotherapy according to the mPE regimen, while 14 out 
of 31 received the mPE chemotherapy in combination with 
bevacizumab.
Clinical results
The treatment was safe in patients with advanced sqNSCLC. 
They received a median number of four treatment courses 
with no significant toxicity or toxicity-related delay among 
the chemotherapy courses. No toxic death, bleeding 
episodes or severe infections were recorded; however, we 
recorded slight hematological toxicity mainly consisting in 
reversible grade 1–3 leukopenia (6 cases) rapidly recovered 
with the use of growth factors, grade 2 anaemia (6 cases), 
grade 1–2 gastroenteric toxicity (3 cases), grade 2–3 
infections (3 cases) and alopecia (16 cases). Two patients 
required blood transfusions after three treatment courses 
and required a 25% cisplatin dose reduction. The latter two 
patients did not show any sign of bleeding and the anaemic 
state was consistent with a clinical picture of cisplatin 
related haematological toxicity which also involved blood 
cells and platelets. No case of treatment-related lethargic 
encephalitis or lung fibrosis was recorded in these patients; 
this was not surprising considering that bevacizumab was 
administered at the dosage of 5 mg/kg which is two/three 
times lower than that commonly used for the treatment of 
non-squamous NSCLC patients. The treatment showed a 
promising antitumor activity in these sqNSCLC patients; 
in fact, complete response (histologically confirmed) 
was obtained in 1, a partial response in 17 out of 31, a 
stable disease in 4 out of 31 and a progressive disease in 
the remaining 9 out of 31 patients, respectively. We also 
recorded a mean PFS and OS of 13.6±4.7 [95% confidence 
interval (CI): 4.344–22.888] and 17±4.4 (95% CI: 8.372–
25.736) months (Figure 1A,B), respectively. Six out of 8 
patients who showed a noteworthy tumor shrinking were 
subjected to lung surgery for tumor resection after four 
treatment courses. These patients gained a significant 
advantage in term of survival [36.6±15.95 (5.3–67.8) vs. 
11.4±1.47 (8.54–14.3) months; P=0.048] (Figure 2A,B,C).
Biological correlations
The mPE chemotherapy regimen +/− bevacizumab 
Figure 1 Kaplan-Meier survival curves for advanced sqNSCLC patients. (A) Mean progression free survival (PFS): 13.6 months (95% CI: 
4.344–22.888); (B) mean overall survival (OS): 17 months (95% CI: 8.372–25.736). sqNSCLC, squamous non-small cell lung cancer.
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showed anti-angiogenic and immunological effects also 
for patients with squamous cell histology. In fact, in this 
patients’ subset, it was observed a treatment-related 
decline in serum levels of VEGF and IL-17, paralleled 
by a significant increase in peripheral blood of activated 
CTLs (CD8+CD62L+), central memory T cells (Tcms) 
(CD8+CD45Ra−CCR7+) and cell lineages expressing the 
phenotype of activated DCs expressing CD83 and the 
dominant co-accessory molecule CD80. In this patients’ 
subset our analysis failed to demonstrate statistically 
significant differences related to the presence or absence of 
bevacizumab in the treatment. Therefore, we investigated 
whether these immunological events, measured at baseline 
and after three treatment courses, correlated with patients’ 
outcome by performing Kaplan Meyer curves and log-rank 
tests. Our analysis recorded a much longer survival 
in those patients who presented lower baseline levels 
of neutrophil-to-lymphocyte ratio (NLR) [L vs. H: 
24.95±8.7 (7.80–42.04) vs. 9.88±3.77 (2.49–17.27) months, 
P=0.05], IL-17A [L vs. H: 4.63±13.6 (7.84–61.44) vs. 
11.0±1.1 (5.14–16.85) months, P=0.036] (Figure 3 A,B), 
peripheral regulatory-T-cells (Tregs) [L vs. H: 40.14±16.6 
(7.57–72.7) vs. 9.9±2.04 (5.9–13.9) months, P=0.02] and 
higher peripheral levels of activated CD83+DC [L vs. H: 
8.4±2.01 (4.45–12.34) vs. 24.0±6.06 (12.12–35.88) months, 
P=0.03] (Figure 4A,B). These data support the hypothesis 
of a strong involvement of immune-system in the outcome 
of these patients. Patients who presented a treatment-
related decrease in IL-17A levels showed a trend to a longer 
survival, which did not achieve statistical significance, 
probably due to the small statistical patient sample. No 
significant differences were, on the other hand, observed for 
other examined parameters.
Discussion
Our retrospective analysis, carried out on a subset of 
thirty-one advanced sqNSCLC patients enrolled in the 
second step of BEVA2007 trial, revealed a 71% disease 
control rate (complete response, partial response and 
stable disease) with a PFS and OS respectively of 13.6±4.7 
(95% CI: 4.34–22.88) and 17±4.4 (95% CI: 8.372–25.736) 
months and a 42% one-year survival rate. Additionally, 
6 (19.3%) patients were down-staged after this treatment 
and could subsequently receive radical surgery achieving 
a median survival of 36 months. Even though significant 
Figure 2 Clinical results on patients undergoing re-surgery. (A) 
Kaplan-Meier survival curve for advanced sqNSCLC patients 
undergoing to surgery vs. patients without surgery. Mean overall 
survival (OS): 36.6 months (95% CI: 5.3–67.8) vs. 11.4 months 
(95% CI: 8.54–14.3) P=0.048. Images of a CT pre- (B) and post- 
treatment (C) of a representative patient subjected to 4 cycles of 
treatment prior to surgery. (B) CE-MDCT, axial plane. Left hilar 
mass with bronchial and vascular infiltration and wide mediastinal 
involvement. (C) CE-MDCT, axial plane. After 3 months 
we observed an important decrease of the mass size with signs 
of central cavitation due to necrosis in absence of mediastinal 
involvement. CE-MDCT, contrast enhanced multi-detector 
computed tomography.
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bias does exist, due to both the small statistical sample of 
the patients and the retrospective nature of our analysis, 
these results appear promising considering that the most 
commonly used chemotherapy doublets induce in these 
patients a response rate of 25–40% and a median survival 
no longer than 9–10 months (4,6). In particular, we found 
that a systemic baseline inflammatory profile characterized 
by a low LNR, low levels of IL-17A and Tregs, and a high 
baseline expression of active DCs (CD83+), is predictive 
of longer survival (19-21). It has been proposed that a 
chronic inflammation status supports tumor progression 
by increasing growth factors, chemokines and cytokines; 
they also promote inflammation-related neo-angiogenesis 
and both homing and differentiation of immune-
suppressive cell lineages like myeloid derived suppressive 
cells (MDSCs) and Tregs (21-25).
 Tregs, whose activation is 
under control of CTLA-1 checkpoint, have the specific 
ability to attenuate the extent of cancer associate immune-
response and represents a common mechanism of immune-
escape for cancer cells (26-29). IL-17A is able to promote 
Figure 3 Kaplan-Meier survival curves for patients with lower (L) or higher (H) baseline levels in neutrophil-to-lymphocyte ratio (NLR) (A) 
and patients with L or H baseline levels of IL-17 (B). Our analysis showed that the patients with L baseline levels in NLR have a longer 
survival than patients with high baseline levels of NLR [mean OS L vs. H: 24.95 months (95% CI: 7.80–42.04) vs. 9.88 months (95% CI: 
2.49–17.27), P=0.05]. Moreover, patients with L baseline levels of IL-17 have a longer survival than patients with H baseline levels of IL-17 
[mean OS L vs. H: 34.63 months (95% CI: 7.84–61.44) vs. 11 (95% CI: 5.14–16.85), P=0.036]. OS, overall survival.
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Figure 4 Kaplan-Meier survival curves for patients with lower (L) or higher (H) baseline levels of peripheral regulatory T cells (Tregs) (A) 
and patients with L or H baseline levels of activated CD83+DC (B). Our analysis showed that the patients with L baseline levels of peripheral 
regulatory T cells (Tregs) have a longer survival than patients with H baseline levels of Tregs [mean OS L vs. H: 40.14 months (95% CI: 7.57–
72.7) vs. 9.9 months (95% CI: 5.9–13.9), P=0.02]. Moreover, patients with H baseline levels of activated CD83+DC have a longer survival 
than patients with low baseline levels of activated CD83+DC [mean OS L vs. H: 8.4 months (95% CI: 4.45–12.34) vs. 24.0 months (95% CI: 
12.12–35.88), P=0.03]. OS, overall survival.
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the switch of inactive Tregs in highly suppressive subsets 
that, in turn, can inhibit all the attempts of immune-system 
and tumor-specific CTLs to counteract tumor growth and 
development (29-32). The decreased levels of VEGF and 
IL-17A following mPE/mPEBev regimen were paralleled 
by the increased percentage of peripheral Tcms and 
activated CD62L+CTLs and by the expansion of activated 
myeloid derivative DCs expressing CD83 and CD80. 
Tcms down-regulate CCR-7 expression and differentiate 
in highly cytotoxic effector cells (effector memory 
(Tem)/CD8
+CD45Ra-CCR7-) or long term memory T cells 
(CD27+) (33-36). An increase of Tcms, therefore, represents 
a new source of antigen specific effector cells able to 
sustain a prolonged immunization with tumor-specific 
cytolytic activity (33-36). In this light, CD8+CD62L+, is 
another very active CTL subset expressing the L selectin 
(CD62L), a trans-membrane protein which allows the 
binding to the specific receptor on tumor vessels and the 
consequent extravasation in the tumor sites (37). In our 
patients, we also found a significant increase of peripheral 
DCs expressing CD83 and CD80, a very efficient antigen 
presenting cell linage able to uptake and process antigen 
released by tumor tissues exposed to the cytotoxic drugs (38). 
Moreover, we recorded a longer survival in those patients 
who showed a higher treatment-related increase in activated 
DCs. These immunological effects, also described in 
previous studies (13,16-18), have been partially related to 
the metronomic modality of administration and can be also 
sustained by bevacizumab. The latter is known for its ability 
in inhibiting endothelial cell proliferation and neo-vessel 
formation and in inducing vessel normalization in cancer 
patients; however, it also promotes neutrophils’, MSDCs’, 
and Tregs’ maturation and induces inhibitory effects on 
DC maturation and CTL precursors’ activation (39-42). 
On this basis, it is not surprising that our metronomic 
chemotherapy +/− bevacizumab exerts immunological effects 
that may affect NSCLC patients’ survival. These results may 
acquire additional interest for the recent development of 
immunotherapy based on PD-1/PDL1 immune-check point 
inhibitors in the treatment of mNSCLC, including squamous 
cell carcinoma (43-48). In this view, the presence of PD1+ T 
cells in tumor tissue is a consequence of pre-existing tumor 
specific immune-response that can be restored by anti-
PD-1/PDL-1 mAbs such as nivolumab, pembrolizumab, and 
atezolizumab. These agents have shown promising antitumor 
activity in different neoplasms including melanoma, NSCLC, 
kidney and colon cancer and it is clear that their efficacy is 
strictly related to a pre-existing antitumor immune-response, 
which has been at least partially attenuated by PD-1/PDL-1 
checkpoint and that is the ultimate weaponry able to kill 
tumor cells.
Conclusions
Based on our results, we believe that a possible way for 
improving the efficacy of mAbs in sqNSCLC patients 
could consist in testing a frontline treatment like mPEBev 
that mobilizes a large number of immune cells inducing 
an antitumor immunization followed by PD-1/PDL-1 
checkpoint inhibitors. In conclusion, the mPE +/− 
bevacizumab regimen is an active treatment for advanced 
sqNSCLC patients and deserves additional evaluation in 
larger studies. Moreover, the immunological effects recorded 
in this trial can represent a solid basis to propose the 
mPE +/− bevacizumab regimen in a sequential combination 
with PD-1/PDL-1 immune-checkpoint inhibitors.
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